Matches in SemOpenAlex for { <https://semopenalex.org/work/W2885393896> ?p ?o ?g. }
- W2885393896 endingPage "e1472195" @default.
- W2885393896 startingPage "e1472195" @default.
- W2885393896 abstract "A number of agents designed for immunotherapy of Acute Myeloid Leukemia (AML) are in preclinical and early clinical development. Most of them target a single antigen on the surface of AML cells. Here we describe the development and key biological properties of a tri-specific agent, the dual-targeting triplebody SPM-2, with binding sites for target antigens CD33 and CD123, and for CD16 to engage NK cells as cytolytic effectors. Primary blasts of nearly all AML patients carry at least one of these target antigens and the pair is particularly promising for the elimination of blasts and leukemia stem cells (LSCs) from a majority of AML patients by dual-targeting agents. The cytolytic activity of NK cells mediated by SPM-2 was analyzed in vitro for primary leukemic cells from 29 patients with a broad range of AML-subtypes. Blasts from all 29 patients, including patients with genomic alterations associated with an unfavorable genetic subtype, were lysed at nanomolar concentrations of SPM-2. Maximum susceptibility was observed for cells with a combined density of CD33 and CD123 above 10,000 copies/cell. Cell populations enriched for AML-LSCs (CD34pos and CD34pos CD38neg cells) from 2 AML patients carried an increased combined antigen density and were lysed at correspondingly lower concentrations of SPM-2 than unsorted blasts. These initial findings raise the expectation that SPM-2 may also be capable of eliminating AML-LSCs and thus of prolonging survival. In the future, patients with a broad range of AML subtypes may benefit from treatment with SPM-2." @default.
- W2885393896 created "2018-08-22" @default.
- W2885393896 creator A5002737974 @default.
- W2885393896 creator A5003069482 @default.
- W2885393896 creator A5012020159 @default.
- W2885393896 creator A5017270208 @default.
- W2885393896 creator A5022434580 @default.
- W2885393896 creator A5024997588 @default.
- W2885393896 creator A5025299367 @default.
- W2885393896 creator A5029902815 @default.
- W2885393896 creator A5035625599 @default.
- W2885393896 creator A5053550462 @default.
- W2885393896 creator A5060766831 @default.
- W2885393896 creator A5071486955 @default.
- W2885393896 creator A5073691481 @default.
- W2885393896 creator A5079605019 @default.
- W2885393896 creator A5081818015 @default.
- W2885393896 creator A5082625244 @default.
- W2885393896 creator A5088187863 @default.
- W2885393896 date "2018-07-30" @default.
- W2885393896 modified "2023-10-17" @default.
- W2885393896 title "Dual-targeting triplebody 33-16-123 (SPM-2) mediates effective redirected lysis of primary blasts from patients with a broad range of AML subtypes in combination with natural killer cells" @default.
- W2885393896 cites W1499346439 @default.
- W2885393896 cites W1563104923 @default.
- W2885393896 cites W1842764967 @default.
- W2885393896 cites W1890235904 @default.
- W2885393896 cites W1906337113 @default.
- W2885393896 cites W1967995010 @default.
- W2885393896 cites W1971760895 @default.
- W2885393896 cites W1972809192 @default.
- W2885393896 cites W1975427849 @default.
- W2885393896 cites W1976187277 @default.
- W2885393896 cites W1977821200 @default.
- W2885393896 cites W1979421565 @default.
- W2885393896 cites W1987981887 @default.
- W2885393896 cites W1989922145 @default.
- W2885393896 cites W1990564763 @default.
- W2885393896 cites W2004530843 @default.
- W2885393896 cites W2006174096 @default.
- W2885393896 cites W2006445674 @default.
- W2885393896 cites W2008748351 @default.
- W2885393896 cites W2009886857 @default.
- W2885393896 cites W2012886748 @default.
- W2885393896 cites W2013971016 @default.
- W2885393896 cites W2019199359 @default.
- W2885393896 cites W2019789998 @default.
- W2885393896 cites W2021404182 @default.
- W2885393896 cites W2022881751 @default.
- W2885393896 cites W2024763401 @default.
- W2885393896 cites W2026721712 @default.
- W2885393896 cites W2028069487 @default.
- W2885393896 cites W2028824678 @default.
- W2885393896 cites W2030249962 @default.
- W2885393896 cites W2041164834 @default.
- W2885393896 cites W2058155210 @default.
- W2885393896 cites W2061635000 @default.
- W2885393896 cites W2062793526 @default.
- W2885393896 cites W2065709542 @default.
- W2885393896 cites W2070387456 @default.
- W2885393896 cites W2070516177 @default.
- W2885393896 cites W2076352025 @default.
- W2885393896 cites W2076922627 @default.
- W2885393896 cites W2077057971 @default.
- W2885393896 cites W2077994554 @default.
- W2885393896 cites W2079127527 @default.
- W2885393896 cites W2084433006 @default.
- W2885393896 cites W2087762900 @default.
- W2885393896 cites W2091609940 @default.
- W2885393896 cites W2091675007 @default.
- W2885393896 cites W2094969550 @default.
- W2885393896 cites W2096420946 @default.
- W2885393896 cites W2100731432 @default.
- W2885393896 cites W2110981938 @default.
- W2885393896 cites W2113752195 @default.
- W2885393896 cites W2114360962 @default.
- W2885393896 cites W2115492737 @default.
- W2885393896 cites W2118820872 @default.
- W2885393896 cites W2120770576 @default.
- W2885393896 cites W2130674465 @default.
- W2885393896 cites W2137605834 @default.
- W2885393896 cites W2137881702 @default.
- W2885393896 cites W2145444883 @default.
- W2885393896 cites W2146300845 @default.
- W2885393896 cites W2150820846 @default.
- W2885393896 cites W2160026729 @default.
- W2885393896 cites W2185042879 @default.
- W2885393896 cites W2232784070 @default.
- W2885393896 cites W2237124828 @default.
- W2885393896 cites W2259451566 @default.
- W2885393896 cites W2284799323 @default.
- W2885393896 cites W2290517386 @default.
- W2885393896 cites W2296846756 @default.
- W2885393896 cites W2521461373 @default.
- W2885393896 cites W2559537906 @default.
- W2885393896 cites W2585283489 @default.
- W2885393896 cites W2594320195 @default.
- W2885393896 cites W2730666287 @default.
- W2885393896 cites W4211249224 @default.